You're signed outSign in or to get full access.
Dean Rosales is a Research Associate specializing in equity research at Wolfe Research LLC, contributing to the analysis of key sectors with a particular focus on company-specific performance. He holds an undergraduate degree from Boston College and an MBA from D'Amore-McKim School of Business, reflecting strong academic credentials. Rosales maintains a FINRA registration through Wolfe Research Securities and has established a significant professional network. His role encompasses detailed coverage and analysis leveraging advanced financial and market insight, supported by a solid foundation in finance and business administration.
Dean Rosales from Wolfe Research questioned if the full-year guidance for revenue per treatment (RPT) growth of 4.5% to 5.5% remains intact.
CFO Joel Ackerman confirmed there is no change to the full-year RPT guidance. He noted that while they expect slightly more contribution from oral phosphate binders, the overall forecast remains within the previously stated range.
Fintool can predict 
DVA's earnings beat/miss a week before the call
